American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

by admin September 29, 2025
September 29, 2025
Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

Denmark’s Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday.

The deal marks a significant expansion of Genmab’s oncology portfolio, adding a promising late-stage cancer therapy candidate to its pipeline.

Under the terms of the agreement, Genmab will pay $97.00 per share, representing a 41% premium over Merus’ closing price of $68.89 on September 26 and a 44% premium over the company’s 30-day volume weighted average price of $67.42.

Both companies’ boards of directors have unanimously approved the transaction.

The acquisition will be funded through a mix of cash on hand and $5.5 billion in non-convertible debt financing.

Genmab has secured a funding commitment from Morgan Stanley Senior Funding Inc., ensuring the deal is not subject to financing conditions.

With this acquisition, Genmab expects to strengthen its position in the competitive biotechnology sector.

“Following the closing of the transaction, Genmab will have four proprietary programs expected to drive multiple new drug launches by 2027,” the companies said in the statement.

Petosemtamab joins Genmab’s late-stage pipeline

At the core of the deal is Merus’ experimental drug petosemtamab, a bispecific antibody targeting EGFRxLGR5, which is currently being tested in two Phase 3 trials for head-and-neck cancer.

Interim results are expected in 2026.

The US Food and Drug Administration has granted petosemtamab two Breakthrough Therapy Designations, covering both first-line and second-line indications.

Data presented earlier this year at the American Society for Clinical Oncology meeting showed encouraging response rates and progression-free survival outcomes compared with the current standard of care.

Genmab said it anticipates the drug’s potential launch in 2027, subject to positive trial outcomes and regulatory approvals.

The company believes the therapy could generate at least $1 billion in annual sales by 2029, with scope for multi-billion-dollar revenues thereafter.

Strategic importance of the deal

Jan van de Winkel, Genmab’s president and chief executive officer, said the deal was consistent with the group’s long-term strategy.

“Petosemtamab has the potential to be a transformational therapy for patients living with head and neck cancer. With our proven track record in development and commercialization, we are confident we can unlock its promise,” he said.

Merus chief executive Bill Lundberg welcomed the deal, citing the companies’ shared focus on innovation in antibody therapeutics.

“We believe Genmab has the right vision and experience to advance petosemtamab in recurrent and metastatic head and neck cancer and beyond,” he said.

Genmab aims to broaden the development of petosemtamab into earlier lines of therapy while leveraging its late-stage expertise and global commercial infrastructure.

Analysts expect the deal to accelerate the company’s transformation into a leading global biotechnology player, providing durable growth into the next decade.

The post Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
European stocks open higher: DAX up 0.47%, FTSE climbs 0.34%
next post
Solana price prediction: top 3 reasons SOL will surge in October

Related Posts

New OpenAI and Microsoft deal paves the way...

September 12, 2025

Top 4 S&P 500 stocks to buy Polymarket...

April 3, 2025

Eli Lilly seen as the stronger bet amid...

June 26, 2025

Europe markets open: equities decline; China sets up...

July 4, 2025

Top 4 hotel stocks to buy as the...

January 25, 2025

European stocks climb as tariff relief offers brief...

April 14, 2025

Amid US-India trade tensions, Motley Fool’s Bill Mann...

September 1, 2025

Renewable energy demand could triple as electricity consumption...

July 26, 2024

Trump-Putin meeting ends with secret ‘sticking points’ and...

August 17, 2025

Nio stock price may surge 75% in 2025:...

February 17, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Europe bulletin: Manchester synagogue attack aftermath, stocks close higher

      October 5, 2025
    • Evening digest: Trump sets deadline for Hamas, Canada’s slowdown, BTC rebounds

      October 5, 2025
    • Iran executes six people for alleged links to Israel, state media reports

      October 5, 2025
    • US digest: Trump’s Hamas ultimatum, government shutdown stalemate continues

      October 5, 2025
    • Japanese stocks may extend record run as Takaichi win revives ‘Abenomics’

      October 5, 2025

    Categories

    • Business (4,191)
    • Investing (2,958)
    • Latest News (2,080)
    • Politics (1,536)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved